Long-acting Spatial Emanators / Repellents (LASER)
NCT07387341 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22815
Last updated 2026-02-04
Summary
Malaria is a major problem in western Kenya, particularly around Lake Victoria. Whilst current prevention methods like bed nets and vaccines help to reduce malaria burden, additional tools are needed to better protect communities from malaria. The investigators will test a new technology called LASER Guardian™, which are devices that release chemicals to keep mosquitoes away from homes. The investigators will conduct a large study involving 69 villages in western Kenya over two years. Each village will be randomly chosen to receive one of three approaches: the new LASER devices, indoor residual spraying with insecticide (a method already known to work), or the standard prevention methods currently used. All villages will continue to receive the usual malaria prevention tools provided by the Kenyan government, including bed nets and vaccines. In villages receiving LASER, the investigators will install 2-3 small device inside structures once a year for two years. In villages receiving IRS, the investigators will spray the inside walls of homes with insecticide once a year for two years. The investigators want to find out if the LASER devices can reduce malaria better than current methods alone, and whether they work as well as indoor spraying. To do this, the investigators will carry out surveys of the community every six months over two years (four rounds in total), testing about 4,485 children between ages 1 and 15 from approximately 3,450 households in each survey to see how many have malaria. The investigators will also work with local health clinics to track malaria cases, study mosquitoes to understand how the interventions affect them, talk with community members about their experiences, and calculate the costs of these different approaches. This study will help us understand whether LASER tool can effectively protecting against malaria in Kenya and other African countries where malaria is common.
Conditions
- Malaria Transmission
- Malaria Prevention
- Malaria
Interventions
- DEVICE
-
Guardian
The SC Johnson long-acting product (Guardian™) is a vapor releasing product (VP) formed from a polyester (PET) mesh substrate carrier dosed with 2,500 mg of transfluthrin per unit (CAS No. 118721-89-3). Transfluthrin is a type I synthetic pyrethroid that acts through modulation of nerve axon sodium channels, causing neurotoxicity in insects. The product is intended to be used as spatial emanator for the control of mosquitoes. The insecticide emanates from the product and subsequently kills or disrupts the biting behaviour of the surrounding vector population. The LASER product will be procured locally from the SC Johnson factory in Nairobi, Kenya (SC Johnson).
- DEVICE
-
IRS with Pirimiphos - methyl
In clusters that are randomised to the IRS arm, IRS will be carried out using pirimiphos-methyl (Actellic®300CS) manufactured by Syngenta, an organophosphate insecticide that is registered for use in Kenya and has demonstrated effectiveness in malaria vector control. The product will be obtained directly from Syngenta to ensure quality and authenticity, with proper documentation and chain of custody maintained throughout the procurement and storage process.
Sponsors & Collaborators
-
Kenya Medical Research Institute
collaborator OTHER -
Institute of Tropical Medicine, Belgium
collaborator OTHER -
Radboud University Medical Center
collaborator OTHER -
Centers for Disease Control and Prevention
collaborator FED -
Liverpool School of Tropical Medicine
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Year
- Max Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-01-17
- Primary Completion
- 2028-04-30
- Completion
- 2028-04-30
Countries
- Kenya
Study Locations
More Related Trials
-
Spatial Repellents for Aedes-borne Virus Control in Sri Lanka
NCT05452447 ·Status: COMPLETED ·Phase: NA
-
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
NCT07385287 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Cluster Randomized Trial to Evaluate Long Lasting Insecticidal Hammocks to Prevent Forest Malaria in Vietnam
NCT00853281 ·Status: COMPLETED ·Phase: NA
-
Attractive Targeted Sugar Bait Trial in Mali
NCT04149119 ·Status: UNKNOWN ·Phase: NA
-
Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults
NCT02014727 ·Status: COMPLETED ·Phase: PHASE1
-
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
NCT06735209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults
NCT06862453 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults
NCT03947190 ·Status: TERMINATED ·Phase: PHASE2
-
Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults
NCT05441410 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali
NCT00863408 ·Status: COMPLETED
-
Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)
NCT01434381 ·Status: COMPLETED ·Phase: PHASE1
-
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
NCT06652737 ·Status: COMPLETED ·Phase: PHASE1
-
GMZ2-Aluminum Hydroxide Phase I, Tübingen
NCT00397449 ·Status: UNKNOWN ·Phase: PHASE1
-
Feasibility of the Vapor Nanobubble Technology for Malaria Diagnostics (MalariaSense)
NCT02672228 ·Status: COMPLETED ·Phase: NA
-
Implementation Research of New Dengue Vector Control Tools
NCT00883441 ·Status: COMPLETED ·Phase: NA
-
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
NCT06268691 ·Status: COMPLETED ·Phase: NA
-
Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar
NCT00318721 ·Status: COMPLETED ·Phase: NA
-
Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP
NCT01142765 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
NCT04343521 ·Status: COMPLETED ·Phase: NA
-
Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
NCT00317473 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites
NCT00890760 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
NCT02015091 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial of the PfSPZ Vaccine
NCT01001650 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad
NCT07038837 ·Status: RECRUITING ·Phase: PHASE4
-
Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali
NCT03510481 ·Status: COMPLETED ·Phase: PHASE1